Crystalline pharmaceutical and methods of preparation and use thereof
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
1. A composition comprising an isolated compound of Formula I:
wherein said compound is synthesized according to a method comprising the steps:
performing hydrolysis of Formula AA with a base:
wherein R is a carbon containing moiety; and
isolating the compound of Formula I,
wherein the hydrolysis is performed in a solution comprising acetone, the composition is essentially free of a chemical catalyst, and the compound of Formula I is isolated by way of recrystallization from a solution comprising acetone.
2. The composition of claim 1 , wherein R is a substituted or unsubstituted group selected from lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, cyclo(lower)alkenyl, aryl, aralkyl, heterocyclyl, and heteroaryl groups.
3. The composition of claim 1 , wherein R is benzyl.
4. The composition of claim 1 , wherein the base is sodium hydroxide.